KCNAB2 and neoplasm: Altogether, the described overexpression of KCNAB2 in tumor epithelium, its solid and consistent association with a poor CRC prognosis, and its association with the three molecular subtypes (CMS1, 2, and 4), which despite having a very different pathway enrichment account for a large percentage of CRC heterogeneity, makes this gene particularly interesting for pharmacological inhibition.